Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study

Fig. 1

Flowchart of the screening profile in Arm 1. Arm 1, the population that underwent PCR-RDB HR-HPV genotyping, Cervista® HR-HPV and cytology assays simultaneously for cervical cancer screening. HPV, human papillomavirus; PCR-RDB HPV, PCR-reverse dot blot high-risk human papillomavirus DNA genotyping assay; Cervista® HPV, Cervista® high-risk human papillomavirus DNA assay; PCR-RDB(−), PCR-RDB HPV assay all HR-HPV types negative; PCR-RDB(+), PCR-RDB HPV assay any of 14 h-HPV types positive; Cervista® (−), Cervista® HR-HPV assay all groups negative; Cervista® (+), Cervista® HR-HPV assay any of the groups positive; CIN, cervical intraepithelial neoplasia; NILM, negative for intraepithelial lesion or malignancy; ≥ ASCUS, atypical squamous cells of undetermined significance or worse, including atypical squamous cells without excluding high-grade lesions and atypical glandular cells; LSIL, low-grade squamous intraepithelial lesion, up to CIN1; HSIL, high-grade squamous intraepithelial lesion, including CIN2 and CIN3; Any HR-HPV, PCR-RDB HR-HPV or Cervista® HR-HPV; Both HR-HPV, PCR-RDB HR-HPV and Cervista® HR-HPV

Back to article page